Ina Nepstad

Consortium of European Social Science Data Archives — Norway

Medicine · Health Sciences

16h-index1.1kcitations25works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(13), PI3K/AKT/mTOR signaling in cancer(6), Myeloproliferative Neoplasms: Diagnosis and Treatment(4), Histone Deacetylase Inhibitors Research(4), Heat shock proteins research(3)

Publications25 total

D8.4 Report on ethical and legal issues and implications for EOSC
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
International Journal of Molecular Sciences·2020· 328 citedOpen Access
Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
Signal Transduction and Targeted Therapy·2019· 71 citedOpen Access
The PI3K-Akt-mTOR intracellular signaling pathway in human acute myeloid leukemia
Bergen Open Research Archive (BORA) (University of Bergen)·2019Open Access
Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison
Expert Opinion on Therapeutic Targets·2018· 17 cited
Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis
Frontiers in Medicine·2018· 65 citedOpen Access
Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism
Expert Opinion on Therapeutic Targets·2017· 27 cited
Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms
Frontiers in Immunology·2017· 86 citedOpen Access
Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
Oncotarget·2017· 2 citedOpen Access
Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells
Expert Opinion on Investigational Drugs·2016· 22 cited
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
Cell Reports·2015· 104 citedOpen Access
Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles
International Journal of Molecular Medicine·2014· 13 citedOpen Access
Co-Activation of AMPK and mTORC1 Is Synthetically Lethal in Acute Myeloid Leukemia
Blood·2014· 1 cited
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia
Expert Review of Hematology·2014· 38 cited
Heat shock protein 70 – the next chaperone to target in the treatment of human acute myelogenous leukemia?
Expert Opinion on Therapeutic Targets·2014· 8 cited
Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation.
PubMed·2014· 13 citedOpen Access
An Extended Study of Seroprevalence of Anti‐<i><scp>A</scp>nisakis simplex</i> IgE Antibodies in <scp>N</scp>orwegian Blood Donors
Scandinavian Journal of Immunology·2013· 33 cited
Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity
Expert Opinion on Investigational Drugs·2013· 10 citedOpen Access
Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
Oncotarget·2013· 44 citedOpen Access
Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors
Expert Opinion on Investigational Drugs·2013· 31 cited
page 1 of 2Next →

Frequent Co-authors

Håkon Reikvam(17), Øystein Bruserud(15), Kimberley Joanne Hatfield(8), Annette K. Brenner(4), Kristin Paulsen Rye(3), Bjørn Tore Gjertsen(3), Ida Sofie Grønningsæter(2), Laury Poulain(2), Étienne Paubelle(2), Florence Zylbersztejn(2), Adrien Grenier(2), Mireille Lambert(2), Jean‐Marie Brusq(2), Edwige Nicodème(2), Justine Decrooqc(2), Alexa S. Green(2), Marie‐Anne Hospital(2), Nathalie Jacque(2), Olivier Hermine(2), Marc Foretz(2)